Insider · CIK 0001767037
Mark William Lowdell
Files at INMB (Inmune Bio, Inc.). First filing -, latest -.
In brief
Mark William Lowdell files SEC Form 4 as officer and 10% owner at INMB (Inmune Bio, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Mark William Lowdell has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 14 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | INMB Inmune Bio, Inc. | MOption exercise Common Stock | +7,211 | $1.40 | $10k | 1,518,017 | Jul 7, 2026 |
| Jul 2, 2026 | INMB Inmune Bio, Inc. | XIn-the-money exercise Common Stock Purchase Warrantderivative | -7,211 | $0.13 | $901 | 7,212 | Jul 7, 2026 |
| Dec 1, 2025 | INMB Inmune Bio, Inc. | AGrant or award Option (right to buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Dec 2, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -400,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +400,000 | - | - | 400,000 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -180,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +180,000 | - | - | 180,000 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -104,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +104,000 | - | - | 104,000 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -140,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +140,000 | - | - | 140,000 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -100,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +100,000 | - | - | 100,000 | Nov 18, 2025 |
| Dec 5, 2024 | INMB Inmune Bio, Inc. | AGrant or award Option (right to buy)derivative | +140,000 | $0.00 | $0 | 140,000 | Dec 9, 2024 |
Questions about Mark William Lowdell
Answered from the filings on this page, as of the latest one.
Is Mark William Lowdell buying or selling?
Mark William Lowdell has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Mark William Lowdell's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mark William Lowdell has 0.
Where does Mark William Lowdell file Form 4?
Mark William Lowdell has filed Form 4 at INMB (Inmune Bio, Inc.) as Chief Scientific Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.